Identification of Potential New Protein Vaccine Candidates through Pan-Surfomic Analysis of Pneumococcal Clinical Isolates from Adults

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Olaya Abril, Alfonso ^a,c,d,e,f   Jiménez Munguía, Irene ^a,c,d,e,f   Gómez Gascón, Lidia ^a   Obando, Ignacio ^b   Rodríguez Ortega, Manuel J ^a,c,d,e,f  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Campus de Excelencia Internacional CeiA3 ^*  (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e Hospital Universitario Reina Sofia   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOPROTEIN; MEMBRANE PROTEIN; P670 2141 PROTEIN; PNEUMOCOCCUS VACCINE; SPR0012 PROTEIN; SPR0328 PROTEIN; SPR0561 PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; LIQUID CHROMATOGRAPHY; PNEUMOCOCCAL INFECTION; SPAIN; STREPTOCOCCUS PNEUMONIAE; TANDEM MASS SPECTROMETRY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN MAPPING; CASE-CONTROL STUDIES; CELL PHYSIOLOGICAL PHENOMENA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEURAL NETWORKS (COMPUTER); NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 84880730624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070365     Document Type: Article

References (71)

1. Blasi F, Mantero M, Santus P, Tarsia P, (2012) Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect 18Suppl 5: 7-14.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
3. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, et al. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7: e1000348.
4. Welte T, Torres A, Nathwani D, (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67: 71-79.
5. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA, (2010) Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 28: 4955-4960.
6. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, et al. (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455-1463.
7. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
8. Grabenstein JD, Klugman KP, (2012) A century of pneumococcal vaccination research in humans. Clin Microbiol Infect 18Suppl 5: 15-24.
9. Musher DM, (2013) How Effective is Vaccination in Preventing Pneumococcal Disease? Infect Dis Clin North Am 27: 229-241.
10. Centers for Disease Control, Prevention (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 61: 816-819.
11. Pittet LF, Posfay-Barbe KM, (2012) Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect 18Suppl 5: 25-36.
12. Weinberger DM, Malley R, Lipsitch M, (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973.
13. Thomas JC, Figueira M, Fennie KP, Laufer AS, Kong Y, et al. (2011) Streptococcus pneumoniae clonal complex 199: genetic diversity and tissue-specific virulence. PLoS One 6: e18649.
14. Assaad U, El-Masri I, Porhomayon J, El-Solh AA, (2012) Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging 7: 453-461.
15. Doro F, Liberatori S, Rodríguez-Ortega MJ, Rinaudo CD, Rosini R, et al. (2009) Surfome analysis as a fast track to vaccine discovery: Identification of a novel protective antigen for group B Streptococcus hyper-virulent strain COH1. Mol Cell Proteomics 8: 1728-1737.
16. Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, et al. (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24: 191-197.
17. van de Rijn I, Kessler RE, (1980) Growth characteristics of group A streptococci in a new chemically defined medium. Infect Immun 27: 444-448.
18. Enright MC, Spratt BG, (1998) A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144: 3049-3060.
19. Olaya-Abril A, Gómez-Gascón L, Jiménez-Munguía I, Obando I, Rodríguez-Ortega MJ, (2012) Another turn of the screw in shaving Gram-positive bacteria: Optimization of proteomics surface protein identification in Streptococcus pneumoniae. J Proteomics 75: 3733-3746.
20. Ardanuy C, Marimón JM, Calatayud L, Giménez M, Alonso M, et al. (2012) Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One 7: e43619.
21. Hausdorff WP, Feikin DR, Klugman KP, (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83-93.
22. Sjöström K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, et al. (2007) Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A 104: 12907-12912.
23. Grau I, Ardanuy C, Calatayud L, Rolo D, Domenech A, et al. (2012) Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. PLoS One 7: e42595.
24. Obando I, Muñoz-Almagro C, Arroyo LA, Tarragó D, Sánchez-Tatay D, et al. (2008) Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 14: 1390-1397.
25. Firacative C, Moreno J, Rosales P, Maldonado A, Sánchez J, et al. (2009) Circulation of Streptococcus pneumoniae clone Colombia 5 ST289 in nine Latin American countries. Rev Panam Salud Publica 25: 337-343.
26. Vanderkooi OG, Church DL, MacDonald J, Zucol F, Kellner JD, (2011) Community-based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLoS One 6: e28547.
27. Porat N, Soley C, Marengolciene MM, Greenberg D, Givon-Lavi N, et al. (2008) An international serotype 3 clone causing pediatric noninvasive infections in Israel, Costa Rica, and Lithuania. Pediatr Infect Dis J 27: 709-712.
28. Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, et al. (2010) Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51: 692-699.
29. Ampofo K, Pavia AT, Chris S, Hersh AL, Bender JM, et al. (2012) The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J 31: 228-234.
30. Grandi G, (2006) Genomics and proteomics in reverse vaccines. Methods Biochem Anal 49: 379-393.
31. Choi CW, Yun SH, Kwon SO, Leem SH, Choi JS, et al. (2010) Analysis of cytoplasmic membrane proteome of Streptococcus pneumoniae by shotgun proteomic approach. J Microbiol 48: 872-876.
32. Soualhine H, Brochu V, Menard F, Papadopoulou B, Weiss K, et al. (2005) A proteomic analysis of penicillin resistance in Streptococcus pneumoniae reveals a novel role for PstS, a subunit of the phosphate ABC transporter. Mol Microbiol 58: 1430-1440.
33. Sun X, Yang XY, Yin XF, Yu G, Xiao CL, et al. (2011) Proteomic analysis of membrane proteins from Streptococcus pneumoniae with multiple separation methods plus high accuracy mass spectrometry. OMICS 15: 683-694.
34. Ling E, Feldman G, Portnoi M, Dagan R, Overweg K, et al. (2004) Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse. Clin Exp Immunol 138: 290-298.
35. Morsczeck C, Prokhorova T, Sigh J, Pfeiffer M, Bille-Nielsen M, et al. (2008) Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 14: 74-81.
36. Grandi G, (2001) Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol 19: 181-188.
37. Gómez-Gascón L, Luque I, Olaya-Abril A, Jiménez-Munguía I, Orbegozo-Medina RA, et al. (2012) Exploring the pan-surfome of Streptococcus suis: looking for common protein antigens. J Proteomics 75: 5654-5666.
38. Mandanici F, Gómez-Gascón L, Garibaldi M, Olaya-Abril A, Luque I, et al. (2010) A surface protein of Streptococcus suis serotype 2 identified by proteomics protects mice against infection. J Proteomics 73: 2365-2369.
39. Dreisbach A, Hempel K, Buist G, Hecker M, Becher D, et al. (2010) Profiling the surfacome of Staphylococcus aureus. Proteomics 10: 3082-3096.
40. Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, et al. (1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62: 5683-5688.
41. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE, (2002) Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70: 2526-2534.
42. Cao J, Chen T, Li D, Wong CK, Chen D, et al. (2008) Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice. Microbes Infect 10: 1536-1542.
43. Gianfaldoni C, Censini S, Hilleringmann M, Moschioni M, Facciotti C, et al. (2007) Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 75: 1059-1062.
44. Gianfaldoni C, Maccari S, Pancotto L, Rossi G, Hilleringmann M, et al. (2009) Sortase A confers protection against Streptococcus pneumoniae in mice. Infect Immun 77: 2957-2961.
45. Glover DT, Hollingshead SK, Briles DE, (2008) Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 76: 2767-2776.
46. Jomaa M, Terry S, Hale C, Jones C, Dougan G, et al. (2006) Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae. Vaccine 24: 5133-5139.
47. Lock RA, Hansman D, Paton JC, (1992) Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 12: 137-143.
48. Lock RA, Paton JC, Hansman D, (1988) Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog 5: 461-467.
49. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, et al. (2011) T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 9: 158-165.
50. Shah P, Swiatlo E, (2006) Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun 74: 5888-5892.
51. Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H, (1996) Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 21: 17-22.
52. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, et al. (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69: 1593-1598.
53. Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE, (1997) Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175: 839-846.
54. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, et al. (2008) Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 205: 117-131.
55. Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT, (2011) Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 79: 238-245.
56. Portnoi M, Ling E, Feldman G, Dagan R, Mizrachi-Nebenzahl Y, (2006) The vaccine potential of Streptococcus pneumoniae surface lectin- and non-lectin proteins. Vaccine 24: 1868-1873.
57. Cardaci A, Papasergi S, Midiri A, Mancuso G, Domina M, et al. (2012) Protective activity of Streptococcus pneumoniae Spr1875 protein fragments identified using a phage displayed genomic library. PLoS One 7: e36588.
58. Cron LE, Stol K, Burghout P, van Selm S, Simonetti ER, et al. (2011) Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun 79: 3697-3710.
59. Green BA, Zhang Y, Masi AW, Barniak V, Wetherell M, et al. (2005) PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 73: 981-989.
60. Hermans PW, Adrian PV, Albert C, Estevao S, Hoogenboezem T, et al. (2006) The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. J Biol Chem 281: 968-976.
61. Kerr AR, Adrian PV, Estevao S, de Groot R, Alloing G, et al. (2004) The Ami-AliA/AliB permease of Streptococcus pneumoniae is involved in nasopharyngeal colonization but not in invasive disease. Infect Immun 72: 3902-3906.
62. Overweg K, Kerr A, Sluijter M, Jackson MH, Mitchell TJ, et al. (2000) The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun 68: 4180-4188.
63. Papasergi S, Garibaldi M, Tuscano G, Signorino G, Ricci S, et al. (2010) Plasminogen- and fibronectin-binding protein B is involved in the adherence of Streptococcus pneumoniae to human epithelial cells. J Biol Chem 285: 7517-7524.
64. Rose L, Shivshankar P, Hinojosa E, Rodriguez A, Sanchez CJ, et al. (2008) Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge. J Infect Dis 198: 375-383.
65. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, et al. (2005) Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A 102: 15641-15646.
66. Garibaldi M, Rodríguez-Ortega MJ, Mandanici F, Cardaci A, Midiri A, et al. (2010) Immunoprotective activities of a Streptococcus suis pilus subunit in murine models of infection. Vaccine 28: 3609-3616.
67. Rodríguez-Ortega MJ, Luque I, Tarradas C, Bárcena JA, (2008) Overcoming function annotation errors in the Gram-positive pathogen Streptococcus suis by a proteomics-driven approach. BMC Genomics 9: 588.
68. Navarre WW, Schneewind O, (1999) Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol Mol Biol Rev 63: 174-229.
69. Ventura CL, Malachowa N, Hammer CH, Nardone GA, Robinson MA, et al. (2010) Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One 5: e11634.
70. Solis N, Larsen MR, Cordwell SJ, (2010) Improved accuracy of cell surface shaving proteomics in Staphylococcus aureus using a false-positive control. Proteomics 10: 2037-2049.
71. Hagerman A, Posfay-Barbe KM, Grillet S, Ochs MM, Brookes RH, et al. (2012) Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia. Clin Microbiol Infect 18: 756-762.